Last reviewed · How we verify
Ciprofloxacin single dose
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Acute bacterial infections (respiratory, urinary tract, gastrointestinal, skin), Gonorrhea (single-dose regimen), Traveler's diarrhea.
At a glance
| Generic name | Ciprofloxacin single dose |
|---|---|
| Sponsor | Bayer |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase; Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As a fluoroquinolone antibiotic, ciprofloxacin binds to and inhibits DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA supercoiling and separation. This dual inhibition leads to disruption of DNA replication, transcription, and ultimately bacterial cell death. The single-dose formulation is designed for rapid therapeutic effect in acute infections.
Approved indications
- Acute bacterial infections (respiratory, urinary tract, gastrointestinal, skin)
- Gonorrhea (single-dose regimen)
- Traveler's diarrhea
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Headache
- Dizziness
- Tendinopathy
- QT prolongation
Key clinical trials
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
- A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia (PHASE1)
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) (PHASE2, PHASE3)
- Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate (PHASE2)
- A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis (PHASE3)
- Antibiotic Prophylaxis Before Shock Wave Lithotripsy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciprofloxacin single dose CI brief — competitive landscape report
- Ciprofloxacin single dose updates RSS · CI watch RSS
- Bayer portfolio CI